CLINICAL TRIALS PROFILE FOR OPDIVO

All Clinical Trials for OPDIVO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01585194 ↗	Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma	Recruiting	Bristol-Myers Squibb	Phase 2	2012-11-01	The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to control uveal melanoma. Ipilimumab is designed to increase the immune system's ability to fight cancer. Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow the body's immune system to work against tumor cells.
NCT01585194 ↗	Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2012-11-01	The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to control uveal melanoma. Ipilimumab is designed to increase the immune system's ability to fight cancer. Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow the body's immune system to work against tumor cells.
NCT01585194 ↗	Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma	Recruiting	M.D. Anderson Cancer Center	Phase 2	2012-11-01	The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to control uveal melanoma. Ipilimumab is designed to increase the immune system's ability to fight cancer. Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow the body's immune system to work against tumor cells.
NCT01592370 ↗	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	Active, not recruiting	Janssen, LP	Phase 1/Phase 2	2012-08-02	The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
NCT01592370 ↗	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	Active, not recruiting	Bristol-Myers Squibb	Phase 1/Phase 2	2012-08-02	The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
NCT01703949 ↗	Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2013-03-20	This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work better in treating patients with CD30+ lymphoma.
NCT01703949 ↗	Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	Recruiting	University of Washington	Phase 2	2013-03-20	This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work better in treating patients with CD30+ lymphoma.

Clinical Trial Conditions for OPDIVO

Condition Name

Condition Name for OPDIVO
Intervention	Trials
Melanoma	44
Non-small Cell Lung Cancer	27
Renal Cell Carcinoma	26
Metastatic Melanoma	23

Condition MeSH

Condition MeSH for OPDIVO
Intervention	Trials
Carcinoma	145
Melanoma	87
Lung Neoplasms	78
Carcinoma, Non-Small-Cell Lung	74

Clinical Trial Locations for OPDIVO

Trials by Country

Trials by Country for OPDIVO
Location	Trials
Brazil	98
Italy	77
Germany	76
Mexico	73
Argentina	71

Trials by US State

Trials by US State for OPDIVO
Location	Trials
California	186
Texas	181
New York	126
Pennsylvania	125
Massachusetts	125

Clinical Trial Progress for OPDIVO

Clinical Trial Phase

Clinical Trial Phase for OPDIVO
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	39
Phase 2/Phase 3	11

Clinical Trial Status

Clinical Trial Status for OPDIVO
Clinical Trial Phase	Trials
Recruiting	249
Active, not recruiting	147
Not yet recruiting	83

Clinical Trial Sponsors for OPDIVO

Sponsor Name

Sponsor Name for OPDIVO
Sponsor	Trials
Bristol-Myers Squibb	287
National Cancer Institute (NCI)	125
M.D. Anderson Cancer Center	43

Sponsor Type

Sponsor Type for OPDIVO
Sponsor	Trials
Other	582
Industry	533
NIH	127